All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary recommendations issued by the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee state that all cancer patients should be prioritized for COVID-19 vaccination, and caregivers and household/close contacts should also be considered for early immunization.1
Due to limited prospective data on vaccination in patients with active malignancies, the preliminary recommendations summarized here are based on expert opinion from the NCCN COVID-19 Vaccination Advisory Committee. The guidance will be updated regularly when new data becomes available.
Local guidelines should be used to decide when to vaccinate cancer patients, alongside guidelines laid out by the US National Academies of Sciences, Engineering, and Medicine (NASEM) Framework for Equitable Allocation of COVID-19 Vaccine. The key principles are as follows:
Recommendations for vaccination timing for patients with hematologic malignancies according to treatment type are laid out in Table 1.
Table 1. A summary of the recommendations for vaccine timing for patients with hematologic malignancies, including those receiving cellular therapies1
Treatment type |
Timing* |
---|---|
Allo-HCT |
At least 3 months post-HCT/cellular therapy** |
Auto-HCT |
|
Cellular therapy |
|
Intensive cytotoxic chemotherapy |
Delay until absolute neutrophil count recovery |
Marrow failure from disease and/or therapy expected to have limited or no recovery |
When vaccine available |
Long-term maintenance therapy |
When vaccine available |
allo-HCT, allogeneic hematopoietic cell transplantation; auto-HCT, autologous hematopoietic cell transplantation. |
In the case of limited availability of COVID-19 vaccines, prioritization among cancer patients should be evidence- and values-based. The following criteria may help with the development of local guidance on vaccine prioritization:
Current vaccines are considered safe and effective in the general population. However, due to the lack of data for immunocompromised patients, cancer patients should be made aware of the importance of following current prevention guidance, postvaccination.
This article summarizes the guidance for COVID-19 vaccination for patients with cancer, including those with hematologic malignancies. Patients with cancer should be prioritized for vaccination, and those of older age, with underlying health conditions, and undergoing treatment should be given further priority. Vaccine timing should be considered in the context of treatment regime. Due to limited postvaccination information, cancer patients and their close contacts should continue to follow the recommendations for COVID-19 prevention, even after receiving the vaccine.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox